{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:37:14Z","timestamp":1793731034569,"version":"4.6.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,7]]},"DOI":"10.7759\/cureus.104809","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T12:41:16Z","timestamp":1772887276000},"source":"Crossref","is-referenced-by-count":1,"title":["Diagnostic and Prognostic Value of CA19-9 in Pancreatic Tumors: A Retrospective Study"],"prefix":"10.7759","author":[{"given":"Feras A","family":"Almbaidin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad E","family":"Alduham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mo'taz  F","family":"Naffa'","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asia  S","family":"Aledwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa  A","family":"Alzubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awad M","family":"Jarrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaid M","family":"Al Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2078-6891.2011.021","article-title":"The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal","volume":"3","author":"Ballehaninna UK","year":"2012","unstructured":"Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J Gastrointest Oncol. 2012, 3:105-19. 10.3978\/j.issn.2078-6891.2011.021","journal-title":"J Gastrointest Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2174\/1566524011313030003","article-title":"The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates","volume":"13","author":"Poruk KE","year":"2013","unstructured":"Poruk KE, Gay DZ, Brown K, et al.. The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med. 2013, 13:340-51. 10.2174\/1566524011313030003","journal-title":"Curr Mol Med"},{"key":"ref3","article-title":"The clinical utility of the CA 19-9 tumor-associated antigen","volume":"85","author":"Steinberg W","year":"1990","unstructured":"Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol. 1990, 85:350-5.","journal-title":"Am J Gastroenterol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1053\/ejso.1999.0925","article-title":"Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice","volume":"26","author":"Mann DV","year":"2000","unstructured":"Mann DV, Edwards R, Ho S, Lau WY, Glazer G. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol. 2000, 26:474-9. 10.1053\/ejso.1999.0925","journal-title":"Eur J Surg Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/s0953-6205(02)00002-x","article-title":"High CA 19-9 levels in benign biliary tract diseases. Report of four cases and review of the literature","volume":"13","author":"Katsanos KH","year":"2002","unstructured":"Katsanos KH, Kitsanou M, Christodoulou DK, Tsianos EV. High CA 19-9 levels in benign biliary tract diseases. Report of four cases and review of the literature. Eur J Intern Med. 2002, 13:132-5. 10.1016\/s0953-6205(02)00002-x","journal-title":"Eur J Intern Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-017-7215-0_15","article-title":"CA 19-9: biochemical and clinical aspects","volume":"867","author":"Scar\u00e0 S","year":"2015","unstructured":"Scar\u00e0 S, Bottoni P, Scatena R. CA 19-9: biochemical and clinical aspects. Adv Exp Med Biol. 2015, 867:247-60. 10.1007\/978-94-017-7215-0_15","journal-title":"Adv Exp Med Biol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2013.10.005","article-title":"Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study","volume":"11","author":"Distler M","year":"2013","unstructured":"Distler M, Pilarsky E, Kersting S, Gr\u00fctzmann R. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study. Int J Surg. 2013, 11:1067-72. 10.1016\/j.ijsu.2013.10.005","journal-title":"Int J Surg"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr561","article-title":"The prognostic and predictive value of serum CA19.9 in pancreatic cancer","volume":"23","author":"Humphris JL","year":"2012","unstructured":"Humphris JL, Chang DK, Johns AL, et al.. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol. 2012, 23:1713-22. 10.1093\/annonc\/mdr561","journal-title":"Ann Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.6288","article-title":"Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704","volume":"26","author":"Berger AC","year":"2008","unstructured":"Berger AC, Garcia M Jr, Hoffman JP, et al.. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol. 2008, 26:5918-22. 10.1200\/JCO.2008.18.6288","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2012.04.035","article-title":"Five year results of US intergroup\/RTOG 9704 with postoperative CA 19-9 \u226490 U\/mL and comparison to the CONKO-001 trial","volume":"84","author":"Berger AC","year":"2012","unstructured":"Berger AC, Winter K, Hoffman JP, et al.. Five year results of US intergroup\/RTOG 9704 with postoperative CA 19-9 \u226490 U\/mL and comparison to the CONKO-001 trial. Int J Radiat Oncol Biol Phys. 2012, 84:e291-7. 10.1016\/j.ijrobp.2012.04.035","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2018.01.003","article-title":"Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: analysis of NRG oncology RTOG trial 9704","volume":"3","author":"Regine WF","year":"2018","unstructured":"Regine WF, Winter K, Abrams RA, et al.. Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: analysis of NRG oncology RTOG trial 9704. Adv Radiat Oncol. 2018, 3:154-62. 10.1016\/j.adro.2018.01.003","journal-title":"Adv Radiat Oncol"},{"key":"ref12","doi-asserted-by":"crossref","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach","volume":"44","author":"DeLong ER","year":"1988","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988, 44:837-45.","journal-title":"Biometrics"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2005.10.005","article-title":"Evidence-based diagnosis and staging of pancreatic cancer","volume":"20","author":"Michl P","year":"2006","unstructured":"Michl P, Pauls S, Gress TM. Evidence-based diagnosis and staging of pancreatic cancer. Best Pract Res Clin Gastroenterol. 2006, 20:227-51. 10.1016\/j.bpg.2005.10.005","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-025-03925-9","article-title":"CA19-9\/DBil: a promising indicator to distinguish between CA19-9-elevated pancreatic head-type autoimmune pancreatitis and pancreatic head cancer","volume":"25","author":"Xi W","year":"2025","unstructured":"Xi W, Liao W, Guo T, et al.. CA19-9\/DBil: a promising indicator to distinguish between CA19-9-elevated pancreatic head-type autoimmune pancreatitis and pancreatic head cancer. BMC Gastroenterol. 2025, 25:306. 10.1186\/s12876-025-03925-9","journal-title":"BMC Gastroenterol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/molecules30092012","article-title":"Early-stage pancreatic cancer diagnosis: serum biomarkers and the potential for aptamer-based biosensors","volume":"30","author":"He W","year":"2025","unstructured":"He W, Cui J, Wang XY, Siu RH, Tanner JA. Early-stage pancreatic cancer diagnosis: serum biomarkers and the potential for aptamer-based biosensors. Molecules. 2025, 30:2012. 10.3390\/molecules30092012","journal-title":"Molecules"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.250","article-title":"Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours","volume":"117","author":"Sefrioui D","year":"2017","unstructured":"Sefrioui D, Blanchard F, Toure E, et al.. Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours. Br J Cancer. 2017, 117:1017-25. 10.1038\/bjc.2017.250","journal-title":"Br J Cancer"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103528","article-title":"A systematic review and meta-analysis of the association between circulating tumor DNA (ctDNA) and prognosis in pancreatic cancer","volume":"168","author":"Guven DC","year":"2021","unstructured":"Guven DC, Sahin TK, Yildirim HC, Aktepe OH, Dizdar O, Yalcin S. A systematic review and meta-analysis of the association between circulating tumor DNA (ctDNA) and prognosis in pancreatic cancer. Crit Rev Oncol Hematol. 2021, 168:103528. 10.1016\/j.critrevonc.2021.103528","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.10232","article-title":"Screening for pancreatic cancer: US Preventive Services Task Force reaffirmation recommendation statement","volume":"322","author":"Owens DK","year":"2019","unstructured":"Owens DK, Davidson KW, Krist AH, et al.. Screening for pancreatic cancer: US Preventive Services Task Force reaffirmation recommendation statement. JAMA. 2019, 322:438-44. 10.1001\/jama.2019.10232","journal-title":"JAMA"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/463193-diagnostic-and-prognostic-value-of-ca19-9-in-pancreatic-tumors-a-retrospective-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T12:41:20Z","timestamp":1772887280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/463193-diagnostic-and-prognostic-value-of-ca19-9-in-pancreatic-tumors-a-retrospective-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.104809","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,7]]}}}